BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T080000
DTEND;TZID=Europe/Brussels:20260325T200000
DTSTAMP:20260521T065957
CREATED:20260219T090517Z
LAST-MODIFIED:20260219T090524Z
UID:9470-1774252800-1774468800@www.europabio.org
SUMMARY:BIO-Europe Spring 2026
DESCRIPTION:EuropaBio is joining BIO-Europe Spring 2026. \n\n\n\nBIO-Europe Spring is Europe’s largest springtime biotech partnering event\, bringing together over 3\,700 leaders and innovators in the life sciences industry. It’s designed for partnering\, business development\, and licensing opportunities in biotechnology and pharmaceuticals. \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T163000
DTEND;TZID=Europe/Brussels:20260323T180000
DTSTAMP:20260521T065957
CREATED:20260317T081056Z
LAST-MODIFIED:20260317T081058Z
UID:9523-1774283400-1774288800@www.europabio.org
SUMMARY:Special feature: Biotech Act Part I – Dr Claire Skentelbery\, Director General EuropaBio @ BIO-Europe Spring 2026
DESCRIPTION:Join our Director General Dr Claire Skentelbery at BIO-Europe Spring on the 23rd of March for an afternoon session dedicated to the EU Biotech Act Part 1. \n\n\n\nThe EU Biotech Act represents a landmark piece of legislation aimed at positioning Europe as a global leader in biotech. Structured in two parts\, the legislative program seeks to drive competitiveness across multiple sectors. Part I of the EU Biotech Act\, published in December 2025\, focuses on advancing health innovation. Key initiatives include accelerating clinical trials\, extending intellectual property protections\, launching a robust investment program\, and introducing strategic projects designed to achieve critical mass in applied innovation. Part II\, set to be unveiled in 2026\, will shift the focus toward maximising biomanufacturing across industries\, further strengthening Europe’s biotech ecosystem. \n\n\n\nThis feature session is dedicated to the Biotech Act part\, including a Keynote and Fireside Chat. \n\n\n\n16:30 Keynote presentation: Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n17:00 Fireside chat: Dr Claire Skentelbery in discussion with Dr Tilo Mandry\, Lead International Liaison Manager IGES \n\n\n\n17:15: Session: Special feature: Biotech Act Part I – What’s in it for me? Industry panel discussionPanelists:– Dr Morgane Rousselot\, Founder\, Chairwoman and CEO\, SeaBeLife Biotech– Dr Ann Belien\, Founder & CEO\, Rejuvenate Biomed (tbc)– Andreas Prenner\, Policy Officer\, European Commission– Dr Marjo Puumalainen\, International Director\, SwedenBIO– Dr Tilo Mandry\, Lead International Liaison Manager\, IGES (Moderator) \n\n\n\nThis panel continues the EU Biotech Act Special Feature: We will discuss what the Biotech Act means for biotech companies and Europe as a biotech investment location\, and how companies can best adapt to its provisions. \n\n\n\nThere are many questions about the Biotech Act:– How will industrial clinical research be accelerated and how will this affect the development of innovative therapies?– How will the Biotech Act impact the financing of innovative biotech start-ups?– Can cell and gene therapies now be developed more quickly by companies in the EU and brought to patients more easily?– What does the extension of intellectual property protection mean for biopharmaceutical companies in practice?– Is the Act sufficiently targeted at industry and where are the risk points?– And finally\, can the EU compete globally\, particularly with the US and China\, thanks to the Biotech Act?We will discuss these and many other important aspects with the panelists and the audience. \n\n\n\n18:00: Close \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/special-feature-biotech-act-part-i-dr-claire-skentelbery-director-general-europabio-bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
END:VCALENDAR